Asia Value & Moat Stocks is a research service for value investors seeking Asia-listed stocks with a huge gap between price and intrinsic value, leaning towards deep value balance sheet bargains (i.e., buying assets at a discount e.g., net cash stocks, net-nets, low P/B stocks, sum-of-the-parts discounts) and wide moat stocks (i.e., buying earnings power at a discount in great companies like "Magic Formula" stocks, high-quality businesses, hidden champions and wide moat compounders). Sign up here to get sta ...

Core Viewpoint - Astrana Health, Inc. (ASTH) is currently positioned as a better value investment compared to Chemed (CHE) based on Zacks Rank and various valuation metrics [3][7]. Valuation Metrics - ASTH has a Zacks Rank of 1 (Strong Buy), indicating a positive earnings outlook, while CHE has a Zacks Rank of 4 (Sell) [3]. - The forward P/E ratio for ASTH is 14.68, significantly lower than CHE's forward P/E of 20.43, suggesting that ASTH is undervalued relative to CHE [5]. - ASTH's PEG ratio is 0.85, indicating better expected earnings growth compared to CHE's PEG ratio of 2.09, which suggests overvaluation [5]. - ASTH has a P/B ratio of 1.74, while CHE's P/B ratio is 5.83, further indicating that ASTH is more attractively priced [6]. Value Grades - ASTH has received a Value grade of A, reflecting its strong valuation metrics, whereas CHE has a Value grade of C, indicating it is less favorable for value investors [6].

Investors looking for stocks in the REIT and Equity Trust sector might want to consider either Apollo Commerical Finance (ARI) or Ladder Capital (LADR) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank favors stocks wi ...

Core Viewpoint - The comparison between Visteon (VC) and Ferrari (RACE) indicates that VC presents a better value opportunity for investors based on various valuation metrics [1][6]. Valuation Metrics - Both Visteon and Ferrari currently hold a Zacks Rank of 1 (Strong Buy), indicating positive earnings estimate revisions and improving earnings outlooks [3]. - Visteon has a forward P/E ratio of 14.57, significantly lower than Ferrari's forward P/E of 50.43, suggesting that VC is more attractively priced [5]. - The PEG ratio for Visteon is 4.89, while Ferrari's PEG ratio is 5.67, indicating that VC may offer better value relative to its expected earnings growth [5]. - Visteon's P/B ratio stands at 2.06, compared to Ferrari's P/B of 33.32, further highlighting the relative undervaluation of VC [6]. - Based on these valuation metrics, Visteon holds a Value grade of A, while Ferrari has a Value grade of F, reinforcing the conclusion that VC is the superior value option [6].

Core Viewpoint - Investors are evaluating Banco Santander (SAN) and Bank of Nova Scotia (BNS) for potential undervalued stock opportunities, with SAN currently showing a stronger earnings outlook and valuation metrics [1][3][7]. Valuation Metrics - SAN has a forward P/E ratio of 9.25, while BNS has a forward P/E of 11.45, indicating SAN may be more attractively priced [5]. - The PEG ratio for SAN is 1.00, compared to BNS's PEG ratio of 1.42, suggesting SAN has a better growth-to-price ratio [5]. - SAN's P/B ratio is 1.17, while BNS's P/B ratio is 1.31, further supporting SAN's valuation advantage [6]. Earnings Outlook - SAN is currently experiencing an improving earnings outlook, which enhances its attractiveness in the Zacks Rank model [7].

Core Viewpoint - The analysis compares Compagnie de Saint-Gobain - Unsponsored ADR (CODYY) and TopBuild (BLD) to determine which stock represents a better undervalued investment opportunity for investors in the Building Products - Miscellaneous sector [1]. Valuation Metrics - CODYY has a forward P/E ratio of 15.83, while BLD has a forward P/E of 19.26, indicating that CODYY may be undervalued compared to BLD [5]. - The PEG ratio for CODYY is 4.12, whereas BLD's PEG ratio is 4.93, suggesting that CODYY has a more favorable earnings growth outlook relative to its valuation [5]. - CODYY's P/B ratio stands at 2.2, compared to BLD's P/B of 5.19, further supporting the argument that CODYY is the more attractive value option [6]. Investment Ratings - CODYY currently holds a Zacks Rank of 2 (Buy), while BLD has a Zacks Rank of 3 (Hold), indicating a stronger earnings outlook for CODYY [3]. - The Value grades for the two companies are B for CODYY and C for BLD, reinforcing the conclusion that CODYY is the superior value option at this time [6].

Investors with an interest in Computer - Peripheral Equipment stocks have likely encountered both LG Display (LPL) and Logitech (LOGI) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, w ...

Core Insights - Investors are comparing Telefonica Brasil (VIV) and Telus (TU) for potential value opportunities in the Diversified Communication Services sector [1] Group 1: Zacks Rank and Earnings Outlook - Telefonica Brasil has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while Telus has a Zacks Rank of 3 (Hold) [3] - The Zacks Rank is based on recent positive revisions to earnings estimates, suggesting that VIV has an improving earnings outlook [3] Group 2: Valuation Metrics - VIV has a forward P/E ratio of 16.19, significantly lower than TU's forward P/E of 21.74 [5] - The PEG ratio for VIV is 0.74, indicating better value compared to TU's PEG ratio of 4.99, which factors in expected earnings growth [5] - VIV's P/B ratio is 1.57, while TU's P/B ratio is 2.13, further highlighting VIV's relative undervaluation [6] Group 3: Value Grades - Based on various valuation metrics, VIV holds a Value grade of A, whereas TU has a Value grade of C, suggesting that VIV is the more attractive option for value investors [6]

Core Insights - Smith & Nephew (SNN) is currently rated as a better value opportunity compared to Stryker (SYK) based on various financial metrics and rankings [1][7] Valuation Metrics - SNN has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while SYK has a Zacks Rank of 3 (Hold) [3] - The forward P/E ratio for SNN is 16.03, significantly lower than SYK's forward P/E of 30.22, suggesting SNN is undervalued [5] - SNN's PEG ratio is 0.97, while SYK's PEG ratio is 2.99, further indicating SNN's better value proposition [5] - SNN has a P/B ratio of 2.63 compared to SYK's P/B of 7.36, reinforcing SNN's favorable valuation metrics [6] - These metrics contribute to SNN's Value grade of A and SYK's Value grade of D, highlighting the disparity in their valuation [6]

Core Viewpoint - Keros Therapeutics, Inc. (KROS) is currently more attractive to value investors compared to Exact Sciences (EXAS) based on various valuation metrics and analyst outlooks [1][3]. Valuation Metrics - KROS has a forward P/E ratio of 70.11, significantly lower than EXAS's forward P/E of 303.06 [5]. - The PEG ratio for KROS is 2.62, while EXAS has a much higher PEG ratio of 10.35, indicating KROS may be undervalued relative to its expected earnings growth [5]. - KROS's P/B ratio stands at 0.81, compared to EXAS's P/B of 3.82, further suggesting KROS is more favorably valued [6]. Analyst Ratings - KROS holds a Zacks Rank of 1 (Strong Buy), while EXAS has a Zacks Rank of 2 (Buy), indicating a stronger earnings estimate revision activity for KROS [3][7]. - The Value grade for KROS is B, whereas EXAS has a Value grade of C, reflecting KROS's superior valuation metrics [6].